Net profit of Bafna Pharmaceuticals rose 5.65% to Rs 2.62 crore in the quarter ended September 2024 as against Rs 2.48 crore during the previous quarter ended September 2023. Sales declined 0.88% to Rs 40.32 crore in the quarter ended September 2024 as against Rs 40.68 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales40.3240.68 -1 OPM %9.429.83 - PBDT4.203.72 13 PBT2.622.48 6 NP2.622.48 6 Powered by Capital Market - Live News

Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 11 November 2024Powered by Capital Market - Live News

Bafna Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 25 September 2024.Powered by Capital Market - Live News

Bafna Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 25 September 2024.Powered by Capital Market - Live News

Net loss of Bafna Pharmaceuticals reported to Rs 0.72 crore in the quarter ended June 2024 as against net profit of Rs 6.35 crore during the previous quarter ended June 2023. Sales declined 20.64% to Rs 33.29 crore in the quarter ended June 2024 as against Rs 41.95 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales33.2941.95 -21 OPM %3.6314.99 - PBDT1.077.56 -86 PBT-0.376.35 PL NP-0.726.35 PL Powered by Capital Market - Live News